IQV Company Profile and Key Details

Q: Who are the executives of IQV?

Mr. Karl GuenaultSenior Vice President & Chief Information OfficerDr. Jeffrey A. SpaederSenior Vice President, Global Chief Medical & Scientific OfficerMr. Ari BousbibChairman, Pres & Chief Executive OfficerMr. Ronald E. BruehlmanExecutive Vice President & Chief Financial OfficerMr. Kevin C. KnightlyPres of Corporation Strategy & Enterprise NetworksMs. Keriann CherofskySenior Vice President, Corporation Controller & Principal Accounting OfficerMr. Eric M. SherbetExecutive Vice President, Gen. Counsel & Sec.Ms. Trudy SteinChief HR Officer & Executive Vice PresidentAndrew MarkwickSenior Vice President of Investor RelationsDr. Cynthia L. VerstPres of Design & Delivery InnovationMr. Nicholas ChildsSenior Vice President of Investor Relations & TreasuryMr. Constantinos PanagosPres of R&D Solutions

NYSE : IQV

IQVIA

$180.96

-21.58-10.65%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

IQVIA Holdings Inc. (IQV) stock declined over -10.65%, trading at $180.96 on NYSE, down from the previous close of $202.54. The stock opened at $199.88, fluctuating between $176.18 and $199.88 in the recent session.

Stock Snapshot

202.54

Prev. Close

30.82B

Market Cap

176.18

Day Low

27.84

P/E Ratio

6.5

EPS (TTM)

8.25

Cash Flow per Share

199.88

Open

170.3M

Number of Shares

199.88

Day High

94.98%

Free Float in %

33.6

Book Value

4.13M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	199.88	199.88	176.07	180.96	4.39M
Feb 04, 2026	201.25	206.00	197.25	202.54	3.38M
Feb 03, 2026	230.08	233.48	201.55	203.77	4.93M
Feb 02, 2026	228.74	231.75	226.57	231.23	805.16K
Jan 30, 2026	234.41	234.87	228.67	230.15	1.46M
Jan 29, 2026	240.33	240.33	233.65	235.62	1.45M
Jan 28, 2026	239.39	241.14	237.47	239.76	1.59M
Jan 27, 2026	237.80	244.16	235.45	241.04	1.31M
Jan 26, 2026	234.76	239.51	227.99	239.43	943.67K
Jan 23, 2026	238.50	239.27	234.69	235.31	683.27K
Jan 22, 2026	242.00	242.99	238.21	239.05	1.31M
Jan 21, 2026	235.92	242.80	233.13	241.40	1.02M
Jan 20, 2026	232.50	237.36	230.65	233.69	1.23M
Jan 16, 2026	240.36	241.55	237.67	237.68	1.35M
Jan 15, 2026	240.89	242.44	238.04	241.28	723.32K
Jan 14, 2026	241.27	242.52	239.69	241.35	881.98K
Jan 13, 2026	242.28	244.82	238.49	241.57	1.12M
Jan 12, 2026	243.41	244.03	239.24	240.86	929.34K
Jan 09, 2026	244.63	247.05	242.41	242.41	1.28M
Jan 08, 2026	241.65	245.22	239.00	243.19	1.82M

Contact Details

Durham, NC 27703

United States

https://www.iqvia.com 919 998 2000

About Company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Stock Peers

MTD

-6.88-0.50%

Mettler-Toledo International Inc.$1,382.85 TMO

-22.86-4.04%

Thermo Fisher Scientific Inc.$542.36 WAT

-7.44-1.94%

Waters Corporation$376.89 DHR

-3.78-1.72%

Danaher Corporation$215.75 DGX

3.07+1.62%

Quest Diagnostics Incorporated$192.30 CRL

-17.92-8.89%

Charles River Laboratories International, Inc.$183.70 A

-3.34-2.51%

Agilent Technologies, Inc.$129.64 RVTY

-4.31-4.15%

Revvity, Inc.$99.52 QGEN

-0.48-0.93%

Qiagen N.V.$51.23 ENZ

-0.0678-17.77%

Enzo Biochem, Inc.$0.31

Company Overview

IQVIA Holdings Inc. (NYSE:IQV) closed at $180.96 USD, losing -$21.58 (-10.65%) from the previous close of $202.54. The stock is currently mid-range between its 52-week high and low $134.65 and $247.05. With a market capitalization of about $30.82 billion, IQVIA Holdings Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.37). Key stats such as the average daily volume over the past year has been around 1.38 million shares, trading with heavier-than-usual volume. Headquartered in Durham, NC, IQVIA Holdings Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Ari Bousbib, the company employs approximately 89,000 people and listed since May 09, 2013. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -22.04%, SMA50 -20.95%, SMA200 -5.6%). The stock’s 14-day RSI is 18.19 (weak momentum), while the ATR of 9.16 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -26.75% below its high and over 34.4% above its low. Average 10-day trading volume of 2.42 million shares is significantly above the 3-month average of 1.40 million, indicating heightened recent market interest.

Valuation Metrics

IQVIA Holdings Inc. trades at a P/E ratio of 22.38, slightly below the S&P 500 average, with a price-to-sales ratio of 1.87 and a price-to-book ratio of 4.68 trading at moderately above to book value. The P/FCF stands at 11.55, also above market averages.

Dividend & Fair Value

IQVIA Holdings Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $232.88. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

IQVIA Holdings Inc. generated EPS of $7.28 over the past year. Five-year average earnings growth is 50.9%. Wall Street analysts project EPS growth of 8.8% annually over the next five years. The latest quarter delivered EPS of $3.00. The next quarter is forecast at $3.39. Next year's EPS is expected at $8.77. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 13 Buy ratings, 8 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $290.00 to $170.00. The high target offers 60.26% upside. The low target suggests -6.06% downside. The mean target is $235.94. This offers 30.38% upside. IQVIA Holdings Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 28, 2025, missed forecasts by 0.67%. The prior quarter beat by 1.44%. Over the last six quarters, Apple has recorded several small beats. These include 3.13% in July 22, 2024.

Shareholding & Insider Activity

IQVIA Holdings Inc. has 170.00 million shares outstanding. The public float is 161.46 million shares, elevated short interest at 4.66% of float. This equals 6.80 million shares. The short ratio is 2.96 days. Institutional investors hold 103.18% of the float. Insiders own 1.05%. CPP Investment Board Private Holdings, Inc. holds 1.57 million shares, CANADA PENSION PLAN INVESTMENT BOARD has 1.57 million shares and BOUSBIB ARI has 820.60 thousand shares. Over the past six months, insider transactions show net selling. They sold 44.54 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, IQVIA generated $15.01B in revenue, or $80.54 per share. Gross margin was 27.56%, operating margin 13.88%, and net profit margin 9.05%. Returns are healthy, with ROA at 5.09% and ROE at 22.22%.
On valuation metrics, IQVIA trades at a P/E of 22.38, P/S of 1.87 and P/B of 4.68. Liquidity is tight, with a current ratio of 0.75 and quick ratio of 0.75. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 87.70 days. Debt-to-equity is 0.32, supported by a cash flow-to-debt ratio of 1.36.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, IQVIA posted revenue of $15.01B, down slightly from $14.41B in the prior quarter. Gross profit was $4.14B (margin 27.56%). Operating income was $2.08B (margin 13.9%). Net income was$1.36B (EPS $7.39).
The company ended the quarter with $1.50B in cash and short-term investments, a total debt of $14.23B, and net debt of $12.86B. Total assets were $26.68B, with equity of $6.11B. Financials further reflected stability, with operating cash flow of $2.15B, free cash flow of $1.50B, and capital expenditures of - $649.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that IQVIA Holdings Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.96%, with price expected at $179.23 by February 19, 2026, within a range of $171.71 to $186.84 3-Month Outlook: Projected fall of -28.3%, reaching $129.74 by May 06, 2026, with a range of $124.62 to $134.83. 1-Year Outlook: Projected gain of 8.39%, with price at $196.15 by February 05, 2027, within a range of $187.04 to $204.55.

Key Takeaways

IQVIA Holdings Inc. (NYSE:IQV) shares are flat 3.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows IQVIA Holdings Inc. trading at a premium to the broader market with a P/E of 22.38. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $243.54, suggesting 34.58% upside. Our AI forecast model points to short-term weakness (-0.96% over two weeks), a medium-term fall (-28.3% over three months), and a longer-term gain (8.39% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current IQVIA Holdings Inc. (IQV) stock price?

IQVIA Holdings Inc. (NYSE: IQV) stock price is $180.96 in the last trading session. During the trading session, IQV stock reached the peak price of $199.88 while $176.18 was the lowest point it dropped to. The percentage change in IQV stock occurred in the recent session was -10.65% while the dollar amount for the price change in IQV stock was - $21.58.

IQV's industry and sector of operation?

The NYSE listed IQV is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. IQVIA Holdings Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IQV?

Mr. Karl Guenault
Senior Vice President & Chief Information Officer
Dr. Jeffrey A. Spaeder
Senior Vice President, Global Chief Medical & Scientific Officer
Mr. Ari Bousbib
Chairman, Pres & Chief Executive Officer
Mr. Ronald E. Bruehlman
Executive Vice President & Chief Financial Officer
Mr. Kevin C. Knightly
Pres of Corporation Strategy & Enterprise Networks
Ms. Keriann Cherofsky
Senior Vice President, Corporation Controller & Principal Accounting Officer
Mr. Eric M. Sherbet
Executive Vice President, Gen. Counsel & Sec.
Ms. Trudy Stein
Chief HR Officer & Executive Vice President
Andrew Markwick
Senior Vice President of Investor Relations
Dr. Cynthia L. Verst
Pres of Design & Delivery Innovation
Mr. Nicholas Childs
Senior Vice President of Investor Relations & Treasury
Mr. Constantinos Panagos
Pres of R&D Solutions

How IQV did perform over past 52-week?

IQV's closing price is 34.39% higher than its 52-week low of $134.65 where as its distance from 52-week high of $247.05 is -26.75%.

How many employees does IQV have?

Number of IQV employees currently stands at 89,000.

Link for IQV official website?

Official Website of IQV is: https://www.iqvia.com

How do I contact IQV?

IQV could be contacted at phone 919 998 2000 and can also be accessed through its website. IQV operates from 4820 Emperor boulevard, Durham, NC 27703, United States.

How many shares of IQV are traded daily?

IQV stock volume for the day was 4.13M shares. The average number of IQV shares traded daily for last 3 months was 1.38M.

What is the market cap of IQV currently?

The market value of IQV currently stands at $30.82B with its latest stock price at $180.96 and 170.3M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	89000
Beta	1.37
Sales or Revenue	$15.01B
5Y Sales Change%	0.595%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

IQV Company Profile and Key Details

IQVIA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways